Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gantenerumab fails; time for Roche to cut its Alzheimer's losses?

This article was originally published in Scrip

Executive Summary

Roche is dropping a Phase III trial of the anti-amyloid gantenerumab in prodromal Alzheimer's disease patients. The decision calls into question not only the future of this drug, but also that of other disease modifying anti-amyloids, including Roche's crenezumab.

You may also be interested in...



Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

EU Pilots New 'Stepwise' Approach To Pediatric Investigation Plans

New EU guidance has been published to help the European Medicines Agency and drug developers agree on the conduct of pediatric investigation plans (PIPs) when crucial information is not yet available. 

UK Industry Urges Government To Drop Statutory Pricing Scheme Rate Hike

The ABPI, which represents the R&D-based pharmaceutical industry in the UK, says the proposed increase in the statutory scheme rebate sends "the worst possible signal" to global investors and boardrooms.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC027291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel